| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2007 | EP1744766A1 Composition for stimulating bone growth and differentiation and method for isolating same |
| 01/24/2007 | EP1744765A2 Materials for medical implants and occlusive devices |
| 01/24/2007 | EP1744764A1 Liposomal formulations of anthracycline agents and cytidine analogs |
| 01/24/2007 | EP1744763A1 Spinosyns for wound healing |
| 01/24/2007 | EP1744761A1 Methods for treating or preventing restenosis and other vascular proliferative disorders |
| 01/24/2007 | EP1744760A2 Pharmaceutical compositions for acute glucocorticoid therapy |
| 01/24/2007 | EP1744759A2 Use of loteprednol etabonate for the treatment of dry eye |
| 01/24/2007 | EP1744758A2 Radiopharmaceutical and methods of synthesis and use thereof |
| 01/24/2007 | EP1744757A1 Improved nsaid composition |
| 01/24/2007 | EP1744756A1 Use of meloxicam formulations in veterinary medicine |
| 01/24/2007 | EP1744754A1 Morpholine compounds |
| 01/24/2007 | EP1744753A1 A method for the treatment or prevention of cardiac hypertrophy |
| 01/24/2007 | EP1744752A2 A method for the prevention of thromboembolic disorders |
| 01/24/2007 | EP1744751A2 Methods for the treatment of synucleinopathies |
| 01/24/2007 | EP1744750A2 Pharmaceutical composition comprising hydrophobic drug having improved solubility |
| 01/24/2007 | EP1744749A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| 01/24/2007 | EP1744748A2 Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes |
| 01/24/2007 | EP1744747A2 Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity |
| 01/24/2007 | EP1744746A2 Use of melatonin in preventing postoperative complications |
| 01/24/2007 | EP1744745A1 Pharmaceutical nitrones |
| 01/24/2007 | EP1744744A2 Bioactive compounds and methods of uses thereof |
| 01/24/2007 | EP1744743A2 Pharmaceutical solution formulations containing 17-aag |
| 01/24/2007 | EP1744742A2 Crystalline and amorphous forms of efaproxiral sodium |
| 01/24/2007 | EP1744741A2 Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer |
| 01/24/2007 | EP1744740A1 Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases |
| 01/24/2007 | EP1744739A2 Use of treprostinil to treat neuropathic diabetic foot ulcers |
| 01/24/2007 | EP1744738A1 Topical preparation containing ambroxol |
| 01/24/2007 | EP1744737A2 Cysteamines for treating complications of hypercholesterolemia and diabetes |
| 01/24/2007 | EP1744736A1 Method of treating dry eye disorders and uveitis |
| 01/24/2007 | EP1744735A2 Method of treatment of myocardial infarction |
| 01/24/2007 | EP1744734A2 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
| 01/24/2007 | EP1744732A2 Nutritional composition for increasing creatine uptake in skeletal muscle |
| 01/24/2007 | EP1744729A2 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| 01/24/2007 | EP1744628A1 Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals |
| 01/24/2007 | EP1744625A1 Micronized organic preservative formulations |
| 01/24/2007 | EP1744619A2 Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| 01/24/2007 | EP1682156B1 Strontium-based complexes, pharmaceutical compositions and dietetic products |
| 01/24/2007 | EP1667992B1 Quinazoline derivatives |
| 01/24/2007 | EP1664053B1 Substituted heterocyclic compounds and methods of use |
| 01/24/2007 | EP1638547B1 Composition for preventing urinary system infections |
| 01/24/2007 | EP1615640B1 Antineoplastic combinations |
| 01/24/2007 | EP1545495A4 P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient |
| 01/24/2007 | EP1545210B1 Stable, low free formaldehyde, synergistic antimicrobial compositions of aldehyde donors and dehydroacetic acid |
| 01/24/2007 | EP1507531B1 Stable pharmaceutical compositions of desloratadine |
| 01/24/2007 | EP1503743B1 Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised |
| 01/24/2007 | EP1503714A4 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 01/24/2007 | EP1461070B1 Combined use of a glp-1 compound and an aldose reductase inhibitor |
| 01/24/2007 | EP1453492B1 Use of quinazolines to treat t-cell mediated diseases |
| 01/24/2007 | EP1452169B1 Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen |
| 01/24/2007 | EP1450785B1 Method of treating dermatoses using avermectin compound |
| 01/24/2007 | EP1448236B1 Inclusion complex of taxol with 2-hxdroxypropyl-beta-cyclodextrin |
| 01/24/2007 | EP1443967B1 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 01/24/2007 | EP1423100B1 Plaster comprising sertaconazole for the treatment of dysfunctions and disorders of nails |
| 01/24/2007 | EP1418894B1 Transdermal therapeutic system with fentanyl |
| 01/24/2007 | EP1408964B1 Use of 2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl|-chromane and its physiologically acceptable salts |
| 01/24/2007 | EP1408939A4 Methods for preparation and use of 1 alpha,24(s)-dihydroxyvitamin d2 |
| 01/24/2007 | EP1377555B1 A dioxino[2,3-g]quinoline-9-carboxylic acid derivative as nk3 receptor antagonist |
| 01/24/2007 | EP1374901B1 Graft rejection suppressors |
| 01/24/2007 | EP1370570B1 Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c |
| 01/24/2007 | EP1363900B1 Isoindole-imide compounds, compositions and uses thereof |
| 01/24/2007 | EP1345594B1 Thermoformable solid pharmaceutical composition for controlled release of ivabradine |
| 01/24/2007 | EP1341537B1 Pharmaceutically active isoindoline derivatives |
| 01/24/2007 | EP1334970B1 Novel ft-0554a substances and process for the preparation thereof |
| 01/24/2007 | EP1309591B1 Substituted pyrazoles |
| 01/24/2007 | EP1284750B1 Pharmaceutical composition |
| 01/24/2007 | EP1280531B1 Formulation consisting of phentolamine mesylate and the use thereof |
| 01/24/2007 | EP1265920B9 Angiogenesis-associated proteins, and nucleic acids encoding the same |
| 01/24/2007 | EP1262482B1 Novel trioxa tricyclic compounds having antimalarial activity |
| 01/24/2007 | EP1257285B1 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 01/24/2007 | EP1180028B1 Il-8 receptor antagonists |
| 01/24/2007 | EP1174151B1 Therapeutic treatment of eosinophilia using chymase inhibitors as the active ingredient |
| 01/24/2007 | EP1126823B1 A process for the preparation of sterile therapeutically acceptable beclomethasone dipropionate |
| 01/24/2007 | EP1123414B1 Antisense modulation of integrin alpha 4 expression |
| 01/24/2007 | EP1100507B1 Use of a combination comprising a precursor of uric acid and antioxidant for the treatment of neurodegenerative deseases |
| 01/24/2007 | EP1067908B9 Taxane microemulsions |
| 01/24/2007 | EP1040102B1 Arylthiazolidinedione derivatives |
| 01/24/2007 | EP1028722B1 Pharmaceutically active composition containing artemisinine and/or a derivative of artemisinine |
| 01/24/2007 | EP1024812B1 Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
| 01/24/2007 | EP1003777B1 PGC-1, A NOVEL BROWN FAT PPARgamma COACTIVATOR |
| 01/24/2007 | EP0968206B8 N-heterocyclic derivatives as nos inhibitors |
| 01/24/2007 | EP0951536B1 Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
| 01/24/2007 | EP0811073B1 Use of immune modulators for making medicaments ot inhibit immune responses against co-administered recombinant viruses |
| 01/24/2007 | CN1902257A Method of preparing carboxylic acid functionalized polymers |
| 01/24/2007 | CN1902232A Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use |
| 01/24/2007 | CN1902216A Depeptidized inhibitors of hepatitis c virus NS3 protease |
| 01/24/2007 | CN1902215A Inhibitors of methionine aminopeptidase-2 and uses thereof |
| 01/24/2007 | CN1902214A Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation |
| 01/24/2007 | CN1902213A Isoflavonoid prodrugs, compositions thereof and therapeutic methods involving same |
| 01/24/2007 | CN1902207A Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin |
| 01/24/2007 | CN1902206A Preparation of 1-aza-2-oxa-dibenzo [e,h] azulenes and their use for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 01/24/2007 | CN1902204A 烟碱性乙酰胆碱受体配体 Nicotinic acetylcholine receptor ligands |
| 01/24/2007 | CN1902203A Diaza-spiropiperidine derivatives as inhibitors of glycine transporter 1 and glycine transporter 2 |
| 01/24/2007 | CN1902201A Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1) |
| 01/24/2007 | CN1902200A 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| 01/24/2007 | CN1902199A 4-amino-quinoline ouinolizidinyl-and quinolizidinylalkyl-derivatives with antimalarial activity |
| 01/24/2007 | CN1902198A Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
| 01/24/2007 | CN1902197A Improved aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
| 01/24/2007 | CN1902196A Thiazole derivative |
| 01/24/2007 | CN1902195A Modulators of cellular adhesion |
| 01/24/2007 | CN1902193A Quinoxalines useful as inhibitors of protein kinases |